Oncology FISH Analysis - MECOM (EVI1)

Clinical Use

Use

Oncology FISH Analysis - MECOM (EVI1) is a Fluorescence In Situ Hybridization (FISH) test aimed at detecting chromosomal rearrangements related to acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). It is crucial for assessing prognosis and disease course in these conditions, which primarily affect adults and stem from undifferentiated white blood cells originating from the bone marrow. The rearrangement within the 3q26.2 region identifies an unfavorable prognosis and should always be interpreted with relevant clinical and pathological data. This assay is particularly useful for patients with suspected diagnoses or when cytogenetic testing has failed, aiding in tracking treatment responses.

Special Instructions

This test is intended for patients with a suspected or confirmed diagnosis of acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndrome. It also serves prognostic purposes for identifying anomalies in diagnosed patients, especially when cytogenetic testing has failed or to monitor therapy responses.

Limitations

This FISH assay is limited to detecting abnormalities at the specified loci; it cannot identify issues outside these areas. Therefore, a negative result does not rule out the presence of other abnormalities that may be clinically significant. Interpretation requires additional clinical information.

Test Details